Thanks:
0
Likes:
0
Dislikes:
0
-
Alchemia Recruits First Patient to Pivotal Phase III Clinical Trial of HA-Irinotecan
(PR-inside.com) BRISBANE, AUSTRALIA -- (Marketwire) -- 01/04/12 -- (ASX: ACL) -- Alchemia Limited is pleased to announce that the first patient in the pivotal Phase III clinical study of its lead cancer drug, HA-Irinotecan, was randomized on Dec 30, 2011 and has now received their first cycle of treatment. HA-Irinotecan is a novel drug formulation that uses Alchemia's HyACT technology to target the widely used chemotherapy drug irinotecan directly to cancer cells. The 390-patient Phase III study will compare the safety and effectiveness of HA-Irinotecan with irinotecan in a double blind trial in second and third line metastatic colorectal cancer patients ..
More...
Tags for this Thread
Posting Permissions
- You may not post new threads
- You may not post replies
- You may not post attachments
- You may not edit your posts
-
Forum Rules
Bookmarks